每经AI快讯，普洛药业（SZ 000739，收盘价：15.14元）11月6日晚间发布公告称，普洛药业股份有限 公司与嘉兴安帝康生物科技有限公司本着平等互利、优势互补的原则，于近日签订了《战略合作框架协 议》，双方基于战略合作关系寻求在创新药物方向更多长期合作项目，共同打造行业竞争力，不断提升 药物市场竞争优势和稳定供应能力。 截至发稿，普洛药业市值为175亿元。 每经头条（nbdtoutiao）——"十五五"新风口！专访五年规划深度参与者董煜：锚定4大新兴产业和6大 未来产业 （记者 王晓波） 本次签署的《战略合作框架协议》仅为框架性协议，不涉及实质性交易，不构成关联交易，也不构成 《上市公司重大资产重组管理办法》规定的重大资产重组。本次战略框架协议的签署无需提请公司董事 会及股东会批准。 2025年1至6月份，普洛药业的营业收入构成为：医药行业占比99.6%，其他业务占比0.4%。 ...

每经AI快讯，11月6日，普洛药业（000739）(000739.SZ)公告称，公司与嘉兴安帝康生物科技签署《战 略合作框架协议》，双方基于战略合作关系寻求在创新药物方向更多长期合作项目，共同打造行业竞争 力，不断提升药物市场竞争优势和稳定供应能力。 ...

普洛药业公告称，近日与嘉兴安帝康生物科技有限公司签订《战略合作框架协议》，就创新药原料药及 中间体研发与外包定制生产项目结成战略合作伙伴，开展长期合作。协议有效期10年，若项目协议届 满、终止或解除则本协议同时终止。该协议不涉及实质性交易，对本年度经营业绩无重大影响，若后续 业务顺利推进，将对未来业绩产生积极影响。不过，具体合作能否达成及协议履行均存在不确定性。公 司近三年签署的框架协议均正常履行。 ...

Core Points - The Shanghai Composite Index is at 3970.29 points with a change of 0.26%, and the total trading volume of A-shares is 1,534.396 billion yuan [1] - A total of 80 A-shares have seen their 5-day moving average cross below the 10-day moving average, indicating potential bearish trends [1] Summary of Companies - **Beifang Copper (000737)**: Today's change is +0.41%, with a 5-day moving average of 15.35 yuan, which is -1.96% lower than the 10-day moving average of 15.66 yuan [1] - **Huali Co., Ltd. (603038)**: Today's change is +2.30%, with a 5-day moving average of 20.29 yuan, which is -1.81% lower than the 10-day moving average of 20.67 yuan [1] - **Suotong Development (603612)**: Today's change is +2.12%, with a 5-day moving average of 24.45 yuan, which is -1.61% lower than the 10-day moving average of 24.85 yuan [1] - **New Lai Materials (300260)**: Today's change is +0.34%, with a 5-day moving average of 58.73 yuan, which is -1.55% lower than the 10-day moving average of 59.65 yuan [1] - **Lianchuang Optoelectronics (600363)**: Today's change is -0.29%, with a 5-day moving average of 61.53 yuan, which is -1.33% lower than the 10-day moving average of 62.36 yuan [1] - **Guangfa Securities (000776)**: Today's change is +0.27%, with a 5-day moving average of 22.61 yuan, which is -1.26% lower than the 10-day moving average of 22.90 yuan [1] - **China Electric Research (688128)**: Today's change is +0.77%, with a 5-day moving average of 31.90 yuan, which is -1.20% lower than the 10-day moving average of 32.29 yuan [1] - **StarNet (002396)**: Today's change is -0.73%, with a 5-day moving average of 26.52 yuan, which is -1.01% lower than the 10-day moving average of 26.79 yuan [1] - **Shan Zi Gaoke (000981)**: Today's change is +1.84%, with a 5-day moving average of 3.94 yuan, which is -0.93% lower than the 10-day moving average of 3.98 yuan [1] - **ST Weier (002058)**: Today's change is +1.78%, with a 5-day moving average of 25.25 yuan, which is -0.92% lower than the 10-day moving average of 25.49 yuan [1] - **Titan Chemical (002145)**: Today's change is +2.80%, with a 5-day moving average of 5.51 yuan, which is -0.85% lower than the 10-day moving average of 5.56 yuan [1] - **Hank Technology (688006)**: Today's change is +2.84%, with a 5-day moving average of 31.95 yuan, which is -0.82% lower than the 10-day moving average of 32.21 yuan [1] - **Inner Mongolia First Machinery (600967)**: Today's change is +0.60%, with a 5-day moving average of 18.61 yuan, which is -0.80% lower than the 10-day moving average of 18.76 yuan [1] - **Liangjiu 12 (301592)**: Today's change is -0.24%, with a 5-day moving average of 124.73 yuan, which is -0.77% lower than the 10-day moving average of 125.69 yuan [1] - **Zhongwu Robotics (688297)**: Today's change is +0.06%, with a 5-day moving average of 47.82 yuan, which is -0.77% lower than the 10-day moving average of 48.19 yuan [1] - **Chihong Zn & Ge (600497)**: Today's change is +0.62%, with a 5-day moving average of 6.63 yuan, which is -0.76% lower than the 10-day moving average of 6.68 yuan [1] - **Dadi (688077)**: Today's change is -0.27%, with a 5-day moving average of 34.01 yuan, which is -0.74% lower than the 10-day moving average of 34.26 yuan [1]

Core Viewpoint - The company has a range of medications available for the treatment of influenza, including Oseltamivir, Amantadine, and a series of Cephalosporins [1] Company Summary - The company, Prolog Pharma (000739.SZ), has confirmed its possession of various antiviral drugs effective against influenza [1]

Core Viewpoint - The company, Pro Pharmaceutical (000739.SZ), confirmed its production of various antiviral medications, including Oseltamivir, Amantadine, and a series of Cephalosporins, which are used for treating influenza, particularly in light of the recent outbreak of a new strain of influenza A [1] Company Summary - Pro Pharmaceutical has a portfolio that includes Oseltamivir, which is a well-known antiviral drug for influenza treatment [1] - The company also produces Amantadine and a range of Cephalosporin antibiotics, indicating a diverse product line in the antiviral and antibiotic sectors [1]

Core Viewpoint - Pro Pharmaceutical Co., Ltd. announced the repurchase of 10,060,000 shares, representing 0.87% of its total share capital as of October 31, 2025 [1] Summary by Category - **Share Repurchase Details** - The company has conducted a share repurchase through a dedicated securities account via centralized bidding [1] - The total number of shares repurchased is 10,060,000 [1] - This repurchase accounts for 0.87% of the company's current total share capital of 1,158,443,576 shares [1]

Core Viewpoint - The company, Prologis Pharmaceutical, has announced a share buyback program, indicating a strategic move to enhance shareholder value through the repurchase of its own shares [1] Summary by Categories Share Buyback - The company has repurchased a total of 10.06 million shares, which represents 0.87% of its current total share capital [1] - The total amount spent on the share buyback is 144 million yuan, excluding transaction fees [1]

Core Viewpoint - Pro Pharmaceutical (000739.SZ) has repurchased a total of 10.06 million shares, representing 0.87% of the company's total share capital, through a centralized bidding transaction as of October 31, 2025 [1] Summary by Category - **Share Repurchase Details** - The maximum transaction price was 15.03 CNY per share, while the minimum transaction price was 13.62 CNY per share [1] - The total amount spent on the repurchase was 144 million CNY, excluding transaction fees [1]

Core Viewpoint - Prolo Pharmaceutical (000739.SZ) has repurchased a total of 10.06 million shares, representing 0.87% of the company's total share capital, through a centralized bidding transaction as of October 31, 2025 [1] Summary by Category - **Share Repurchase Details** - The maximum transaction price was 15.03 CNY per share, while the minimum transaction price was 13.62 CNY per share [1] - The total amount spent on the repurchase was 144 million CNY, excluding transaction fees [1]